{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:12:17Z","timestamp":1784045537007,"version":"3.55.0"},"reference-count":21,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Appendage Disord"],"abstract":"<jats:p>Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a disproportionately high burden of metabolic comorbidities, including obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM), dyslipidaemia, and polycystic ovary syndrome. Despite this, clinical management of HS has historically remained siloed within dermatology, with insufficient integration of cardiometabolic risk management. Summary: GLP-1 receptor agonists (GLP-1 RAs) \u2013 a drug class now established for T2DM, obesity, and cardiovascular risk reduction \u2013 have recently emerged as candidate agents for HS. A systematic review published in 2024 and two pivotal real-world studies published in 2025 provide preliminary evidence that GLP-1 RAs improve HS disease activity through both weight loss and direct anti-inflammatory mechanisms. We argue that this evidence base is already sufficient to justify a paradigm shift: GLP-1 RAs should be considered as adjunctive components of a multidisciplinary treatment strategy for HS patients with concurrent cardiometabolic disease. We propose a practical clinical framework for patient selection and monitoring and call for dedicated randomised controlled trials. Key Messages: Metabolic comorbidities are mechanistically linked to HS pathogenesis and are inadequately addressed in current clinical practice. GLP-1 RAs offer dual benefit in HS \u2013 improving both metabolic outcomes and HS disease activity. Dermatologists should screen every HS patient for cardiometabolic comorbidities and advocate for GLP-1 RA therapy in eligible patients as part of a multidisciplinary approach.<\/jats:p>","DOI":"10.1159\/000552598","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:00:42Z","timestamp":1778947242000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient"],"prefix":"10.1159","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2450-6512","authenticated-orcid":false,"given":"Gerardo Uriel","family":"Viquez Burboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel Rafael","family":"Flores Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0201"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14024"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17186"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14500"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.10.020"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13777"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.042"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.70035"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15910"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403347"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032183"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16892"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15233"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2723"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.11.039"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.6264"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.059"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"}],"container-title":["Skin Appendage Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:01:40Z","timestamp":1784044900000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1159\/000552598","archive":["Portico"],"relation":{},"ISSN":["2296-9195","2296-9160"],"issn-type":[{"value":"2296-9195","type":"print"},{"value":"2296-9160","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]}}}